The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
Abstract
Current drug discovery strategies include both molecular and empirical approaches. The molecular approaches are predominantly hypothesis-driven and are referred to as target-based. The empirical approaches are referred to as phenotypic because they rely on phenotypic measures of response. A recent analysis revealed the phenotypic approaches to be the more successful strategy for small-molecule, first-in-class medicines. The rationalization for this success was the unbiased identification of the molecular mechanism of action (MMOA).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Self-citationGlivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
Garcia-Calvo, M., Lisnock, J., Bull, H. G., Hawes, B. E., Burnett, D. A., Braun, M. P., Crona, J. H., Davis, H. R., Dean, D. C., Detmers, P. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500269102 · Cited by 670
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
Chung, C.-W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200108t · Cited by 334
Cited by
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Natural Products in Cancer Therapy: Past, Present and Future
Huang, M., Lu, J.-J., & Ding, J. (2021) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00293-7 · Cited by 648
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping
Wu, Y., Zhang, F., Yang, K., Fang, S., Bu, D., Li, H., Sun, L., Hu, H., Gao, K., Wang, W., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1021 · Cited by 561
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Metadata
- Authors
- Swinney, D. C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-04
- Volume
- 93
- Issue
- 4
- Pages
- 299-301
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2013614403
- Cited by
- 413
- References
- 5
- FWCI
- 29.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.